<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7402116\results\search\disease\results.xml">
  <result pre="RNA viruses that originate in animal reservoirs and include severe" exact="acute" post="respiratory distress syndrome (SARS) and Middle East respiratory syndrome"/>
  <result pre="viruses that originate in animal reservoirs and include severe acute" exact="respiratory" post="distress syndrome (SARS) and Middle East respiratory syndrome (MERS)"/>
  <result pre="originate in animal reservoirs and include severe acute respiratory distress" exact="syndrome" post="(SARS) and Middle East respiratory syndrome (MERS) and other"/>
  <result pre="include severe acute respiratory distress syndrome (SARS) and Middle East" exact="respiratory" post="syndrome (MERS) and other inconsequential coronaviruses from human reservoirs"/>
  <result pre="severe acute respiratory distress syndrome (SARS) and Middle East respiratory" exact="syndrome" post="(MERS) and other inconsequential coronaviruses from human reservoirs like"/>
  <result pre="(ACE-2) receptor and binds to hemoproteins, resulting in a severe" exact="systemic" post="inflammatory response, particularly in high ACE-2 organs like the"/>
  <result pre="ACE-2 organs like the lungs, heart, and kidney, resulting in" exact="systemic" post="disease. The inflammatory response manifested by increased cytokine levels"/>
  <result pre="subsequent loss of cytoprotection. This has been seen in other" exact="viral" post="illness like human immunodeficiency virus (HIV), Ebola, and SARS/MERS."/>
  <result pre="This has been seen in other viral illness like human" exact="immunodeficiency" post="virus (HIV), Ebola, and SARS/MERS. There are a number"/>
  <result pre="clinical promise. This illness disproportionately affects patients with obesity, a" exact="chronic" post="inflammatory disease with a baseline excess of cytokines. The"/>
  <result pre="This illness disproportionately affects patients with obesity, a chronic inflammatory" exact="disease" post="with a baseline excess of cytokines. The majority of"/>
  <result pre="an RNA virus that shares the same subgenus as severe" exact="acute" post="respiratory distress syndrome (SARS) [1]. Human coronaviruses include the"/>
  <result pre="RNA virus that shares the same subgenus as severe acute" exact="respiratory" post="distress syndrome (SARS) [1]. Human coronaviruses include the common"/>
  <result pre="that shares the same subgenus as severe acute respiratory distress" exact="syndrome" post="(SARS) [1]. Human coronaviruses include the common cold and"/>
  <result pre="cold and are generally inconsequential. Both SARS and Middle East" exact="respiratory" post="syndrome (MERS) came from animal reservoirs and caused global"/>
  <result pre="and are generally inconsequential. Both SARS and Middle East respiratory" exact="syndrome" post="(MERS) came from animal reservoirs and caused global epidemics."/>
  <result pre="may provide insight into the pathophysiologic process occurring with COVID-19" exact="infection" post="and possible treatment options. The HO system, which comprises"/>
  <result pre="bilirubin (antioxidant), and carbon monoxide (antiapoptotic) is critical in its" exact="primary" post="role in cellular defense is involved in a variety"/>
  <result pre="include cytoprotection, anti-inflammation, anti-oxidative effects, apoptosis, neuromodulation, immune-modulation, angiogenesis, and" exact="vascular" post="regulation [6]. Increased levels of HO-1 expression also results"/>
  <result pre="anti-oxidative effects, apoptosis, neuromodulation, immune-modulation, angiogenesis, and vascular regulation [6]." exact="Increased" post="levels of HO-1 expression also results from numerous forms"/>
  <result pre="Free Heme and Decreases Functional Hemoprotein COVID-19 produces a severe" exact="systemic" post="inflammatory reaction, likely the result of increased free heme"/>
  <result pre="as the lungs (endothelium), kidney, liver, gastrointestinal (GI) tract, testes," exact="and heart" post="[8]. 3. How COVID-19-Cytokine Storm Inhibits HO-1 Inhibitors of"/>
  <result pre="the lungs (endothelium), kidney, liver, gastrointestinal (GI) tract, testes, and" exact="heart" post="[8]. 3. How COVID-19-Cytokine Storm Inhibits HO-1 Inhibitors of"/>
  <result pre="enzyme heme oxygenase [9,10,11,12,13,14,15]. Tin (Sn4+) has been used to" exact="lower" post="bilirubin levels in newborns to treat hyperbilirubinemia in newborns"/>
  <result pre="been used to lower bilirubin levels in newborns to treat" exact="hyperbilirubinemia" post="in newborns [6]. HO-1 cleaves the tetrapyrrole ring at"/>
  <result pre="dying cells has additive toxic effects. Murine models of HO-1" exact="deficiency" post="demonstrate a loss of stress defenses and increased toxicity"/>
  <result pre="and increased toxicity from free iron [20,21,22]. Humans with HO-1" exact="deficiency" post="resulted in death at an early age [23,24], as"/>
  <result pre="fact that they all inhibit CYP production which results in" exact="lower" post="heme production [29]. 5. Consequences of Hemoprotein Malfunction/Deficiency The"/>
  <result pre="catalase, and the cytochromes of the ETC in the mitochondria." exact="Deficiency of" post="any of these hemoproteins cause tissue inflammation and organ"/>
  <result pre="hemoproteins cause tissue inflammation and organ damage and even a" exact="prothrombotic state" post="(Table 1). Many COVID-19 patients require prolonged periods of"/>
  <result pre="causes in hemoglobin leading to the displacement of iron [7]." exact="Deficiency of" post="human HO-1 causes early death as a result of"/>
  <result pre="causes early death as a result of severe iron toxicity," exact="renal failure," post="and nephrotic range proteinuria, the same clinical issues we"/>
  <result pre="affected by COVID-19. A significant number of COVID-19 patients experience" exact="rhabdomyolysis" post="due to COVID-19 directly binding the porphyrin substrate of"/>
  <result pre="the release of hemoprotein and iron, which induces inflammation and" exact="muscle" post="breakdown [31,32,33,34]. This has previously been shown in HO-1"/>
  <result pre="muscle breakdown [31,32,33,34]. This has previously been shown in HO-1" exact="deficiency" post="in vitro and in vivo [35,36,37]. It has been"/>
  <result pre="who have an impaired NO pathway include those with hypertension," exact="diabetes mellitus," post="and atherosclerosis, patients observed to have worse outcomes from"/>
  <result pre="and atherosclerosis, patients observed to have worse outcomes from COVID-19" exact="infection" post="[41]. In the kidney, NO functions to regulate renal"/>
  <result pre="[41]. In the kidney, NO functions to regulate renal hemodynamics," exact="medullary" post="perfusion, natriuresis, tubuloglomerular feedback, inhibition of tubular sodium reabsorption,"/>
  <result pre="more susceptible to diseases that involve the endothelium of the" exact="cardiovascular" post="system including abdominal aortic aneurysms, atherosclerosis, and coronary artery"/>
  <result pre="of the cardiovascular system including abdominal aortic aneurysms, atherosclerosis, and" exact="coronary artery disease," post="especially in diabetes and obesity [46,49,50]. Other diseases such"/>
  <result pre="the cardiovascular system including abdominal aortic aneurysms, atherosclerosis, and coronary" exact="artery disease," post="especially in diabetes and obesity [46,49,50]. Other diseases such"/>
  <result pre="abdominal aortic aneurysms, atherosclerosis, and coronary artery disease, especially in" exact="diabetes" post="and obesity [46,49,50]. Other diseases such as emphysema and"/>
  <result pre="aortic aneurysms, atherosclerosis, and coronary artery disease, especially in diabetes" exact="and obesity" post="[46,49,50]. Other diseases such as emphysema and melanoma were"/>
  <result pre="aneurysms, atherosclerosis, and coronary artery disease, especially in diabetes and" exact="obesity" post="[46,49,50]. Other diseases such as emphysema and melanoma were"/>
  <result pre="especially in diabetes and obesity [46,49,50]. Other diseases such as" exact="emphysema" post="and melanoma were also more prevalent in patients with"/>
  <result pre="diabetes and obesity [46,49,50]. Other diseases such as emphysema and" exact="melanoma" post="were also more prevalent in patients with larger GT"/>
  <result pre="associated with mild beneficial glycemic control [52,53]. HO-1 levels are" exact="lower" post="in those with longer GT sequences predisposing patients to"/>
  <result pre="decreased endothelial hemostasis [46,47,48,49,50,51,52]. Individuals with long GT repeats had" exact="lower" post="bilirubin and ferritin levels [54], reviewed in [55], and"/>
  <result pre="lymphoblastoid cell lines with longer GT sequences [49]. That is," exact="short" post="alleles of the GT repeat are associated with greater"/>
  <result pre="done to determine if there is a correlation. Patients with" exact="Gilbert syndrome" post="are known to have shorter GT sequences and elevated"/>
  <result pre="to determine if there is a correlation. Patients with Gilbert" exact="syndrome" post="are known to have shorter GT sequences and elevated"/>
  <result pre="levels and bilirubin [46,56,57,58]. These patients are well protected from" exact="cardiovascular disease" post="due to a lower inflammatory state given the increase"/>
  <result pre="and bilirubin [46,56,57,58]. These patients are well protected from cardiovascular" exact="disease" post="due to a lower inflammatory state given the increase"/>
  <result pre="patients are well protected from cardiovascular disease due to a" exact="lower" post="inflammatory state given the increase in bilirubin and HO-1"/>
  <result pre="findings further support that shorter GT sequences lead to a" exact="lower" post="inflammatory state. COVID-19 has worse outcomes in the obese"/>
  <result pre="6 (IL-6) from insulin and leptin resistance [59,60]. Obese and" exact="metabolic syndrome" post="patients have both insulin and leptin resistance leading to"/>
  <result pre="(IL-6) from insulin and leptin resistance [59,60]. Obese and metabolic" exact="syndrome" post="patients have both insulin and leptin resistance leading to"/>
  <result pre="pathways resulting in inflammation [62]. Insulin resistance also results in" exact="chronic" post="very low density lipoprotein (VLDL) secretion and increased delivery"/>
  <result pre="excess, will lead to induction of insulin resistance irrespective of" exact="obesity" post="[63]. There are many reasons for the negative clinical"/>
  <result pre="are many reasons for the negative clinical outcomes in the" exact="chronic" post="inflammatory state of obesity as result of COVID-19 [60]."/>
  <result pre="the negative clinical outcomes in the chronic inflammatory state of" exact="obesity" post="as result of COVID-19 [60]. Peterson et al. have"/>
  <result pre="result of COVID-19 [60]. Peterson et al. have shown that" exact="obesity" post="increases the oxidation of high-density lipoprotein (HDL) [64]. Oxidized"/>
  <result pre="causes an inflammatory cascade with inflammatory cytokines, interleukins (IL-6, IL-1)," exact="tumor" post="necrosis factor (TNF), and upregulation of Angiotensin II (ANG"/>
  <result pre="Angiotensin II (ANG II), a biomarker for early detection of" exact="cardiovascular" post="risk [64]. This made obese subjects susceptible to early"/>
  <result pre="cardiovascular risk [64]. This made obese subjects susceptible to early" exact="heart" post="failure and death subsequent to COVID-19 infection [66]. We"/>
  <result pre="susceptible to early heart failure and death subsequent to COVID-19" exact="infection" post="[66]. We showed that humans and mice with obesity"/>
  <result pre="COVID-19 infection [66]. We showed that humans and mice with" exact="obesity" post="display low left ventricle function [67]. In a study"/>
  <result pre="adiponectin, marked elevation of Ox-HDL, and circulating endothelial cells (CEC)." exact="Obesity" post="increases the volume of epicardial fat and subsequent inflammation"/>
  <result pre="mitochondrial enzymes and destruction of mitochondria [68]. This negatively affected" exact="cardiovascular" post="outcomes in obesity including heart failure and arrhythmias, even"/>
  <result pre="destruction of mitochondria [68]. This negatively affected cardiovascular outcomes in" exact="obesity" post="including heart failure and arrhythmias, even prior to COVID-19"/>
  <result pre="mitochondria [68]. This negatively affected cardiovascular outcomes in obesity including" exact="heart" post="failure and arrhythmias, even prior to COVID-19 infection. Increased"/>
  <result pre="including heart failure and arrhythmias, even prior to COVID-19 infection." exact="Increased" post="antioxidant and HO-1-derived bilirubin may ameliorate the negative effect"/>
  <result pre="of brown fat [71]. White fat is proinflammatory and has" exact="lower" post="concentrations of mitochondria than brown fat [72]. Mitochondria is"/>
  <result pre="to peroxynitrite which is directly toxic to DNA and the" exact="vascular" post="endothelium. The severity of the cytokine storm will inhibit"/>
  <result pre="more ROS formation as HO-1 levels in these individuals are" exact="lower" post="at baseline with less inducibility, and therefore, lower CO"/>
  <result pre="individuals are lower at baseline with less inducibility, and therefore," exact="lower" post="CO levels are produced from the degradation of heme"/>
  <result pre="Moreover, adipocyte specific HO-1 gene expression is effective in restoring" exact="vascular" post="function, insulin sensitivity, the conversion of white adipocytes to"/>
  <result pre="mitochondrial function [91]. 7. Clinical Presentation Patients can be mildly" exact="symptomatic" post="to severely ill with multi-organ damage/failure, multifocal pneumonia with"/>
  <result pre="be mildly symptomatic to severely ill with multi-organ damage/failure, multifocal" exact="pneumonia" post="with acute respiratory distress syndrome (ARDS), rhabdomyolysis, anemia with"/>
  <result pre="symptomatic to severely ill with multi-organ damage/failure, multifocal pneumonia with" exact="acute" post="respiratory distress syndrome (ARDS), rhabdomyolysis, anemia with increased oxygen"/>
  <result pre="to severely ill with multi-organ damage/failure, multifocal pneumonia with acute" exact="respiratory" post="distress syndrome (ARDS), rhabdomyolysis, anemia with increased oxygen requirements,"/>
  <result pre="ill with multi-organ damage/failure, multifocal pneumonia with acute respiratory distress" exact="syndrome" post="(ARDS), rhabdomyolysis, anemia with increased oxygen requirements, and elevated"/>
  <result pre="damage/failure, multifocal pneumonia with acute respiratory distress syndrome (ARDS), rhabdomyolysis," exact="anemia" post="with increased oxygen requirements, and elevated liver enzymes. Most"/>
  <result pre="requirements, and elevated liver enzymes. Most commonly, they will have" exact="leukopenia" post="and lymphopenia, with a reversal of the CD4/CD8 ratio"/>
  <result pre="and lymphopenia, with a reversal of the CD4/CD8 ratio [92]." exact="Elevated" post="C-reactive protein (CRP) and ferritin levels suggest an impending"/>
  <result pre="(CRP) and ferritin levels suggest an impending cytokine storm [93]." exact="Elevated" post="D-dimers suggest the likelihood of deep vein thrombosis and"/>
  <result pre="impending cytokine storm [93]. Elevated D-dimers suggest the likelihood of" exact="deep vein thrombosis" post="and venous thromboembolism (DVT/VTE) and anticoagulation must be considered"/>
  <result pre="storm [93]. Elevated D-dimers suggest the likelihood of deep vein" exact="thrombosis" post="and venous thromboembolism (DVT/VTE) and anticoagulation must be considered"/>
  <result pre="Elevated D-dimers suggest the likelihood of deep vein thrombosis and" exact="venous thromboembolism" post="(DVT/VTE) and anticoagulation must be considered [94,95]. COVID-19 patients"/>
  <result pre="anticoagulation must be considered [94,95]. COVID-19 patients can present with" exact="acute" post="kidney injury complicated by acute renal failure, nephrotic range"/>
  <result pre="must be considered [94,95]. COVID-19 patients can present with acute" exact="kidney injury" post="complicated by acute renal failure, nephrotic range proteinuria, and/or"/>
  <result pre="COVID-19 patients can present with acute kidney injury complicated by" exact="acute" post="renal failure, nephrotic range proteinuria, and/or electrolyte derangements [96]."/>
  <result pre="patients can present with acute kidney injury complicated by acute" exact="renal failure," post="nephrotic range proteinuria, and/or electrolyte derangements [96]. Older patients"/>
  <result pre="and/or electrolyte derangements [96]. Older patients have comorbid conditions like" exact="hypertension" post="and diabetes [41]. Younger patients have more pronounced obesity"/>
  <result pre="derangements [96]. Older patients have comorbid conditions like hypertension and" exact="diabetes" post="[41]. Younger patients have more pronounced obesity and the"/>
  <result pre="like hypertension and diabetes [41]. Younger patients have more pronounced" exact="obesity" post="and the chronic inflammatory state that it implies [60]."/>
  <result pre="diabetes [41]. Younger patients have more pronounced obesity and the" exact="chronic" post="inflammatory state that it implies [60]. The organs mainly"/>
  <result pre="that it implies [60]. The organs mainly affected by COVID-19" exact="infection" post="includes the lungs (i.e., the endothelium of the pulmonary"/>
  <result pre="COVID-19 infection includes the lungs (i.e., the endothelium of the" exact="pulmonary" post="vasculature), kidneys, liver, and arterial endothelium (as evidenced by"/>
  <result pre="COVID-19 to infect cells. There is concern that patients with" exact="hypertension" post="on ACE inhibitors and angiotensin II receptor blockers (ARBâ€™s)"/>
  <result pre="II receptor blockers (ARBâ€™s) might have an increased risk of" exact="infection" post="[97]. Since these drugs may upregulate ACE-2 expression, are"/>
  <result pre="that ACEI/ARB therapy is not associated with increased risk of" exact="disease" post="or severity of illness [99]. COVID-19 patients present with"/>
  <result pre="ALT (alanine aminotransferase), elevated CRP (c-reactive protein), elevated D-dimer, and" exact="thrombocytopenia" post="[100,101,102]. Initial imaging findings typically reveal bilateral infiltrates, unilateral"/>
  <result pre="elevated D-dimer, and thrombocytopenia [100,101,102]. Initial imaging findings typically reveal" exact="bilateral" post="infiltrates, unilateral infiltrates, or pleural effusion [100,101,102]. The overall"/>
  <result pre="and thrombocytopenia [100,101,102]. Initial imaging findings typically reveal bilateral infiltrates," exact="unilateral" post="infiltrates, or pleural effusion [100,101,102]. The overall clinical presentation"/>
  <result pre="Initial imaging findings typically reveal bilateral infiltrates, unilateral infiltrates, or" exact="pleural" post="effusion [100,101,102]. The overall clinical presentation of COVID-19 patients"/>
  <result pre="The basis for COVID-19 causing morbidity and mortality is severe" exact="systemic" post="inflammation. This is the result of increased heme and"/>
  <result pre="research to treat COVID-19 has focused on direct inhibition of" exact="viral" post="replication and the inflammatory response. 8. Cytochrome 2D6 Genetic"/>
  <result pre="Hydroxychloroquine/chloroquine are both 4-aminoquinolones approved in the treatment of Malaria," exact="Systemic" post="Lupus Erythematosus, and Rheumatoid Arthritis [103]. The FDA approved"/>
  <result pre="are both 4-aminoquinolones approved in the treatment of Malaria, Systemic" exact="Lupus Erythematosus," post="and Rheumatoid Arthritis [103]. The FDA approved these drugs"/>
  <result pre="in the treatment of Malaria, Systemic Lupus Erythematosus, and Rheumatoid" exact="Arthritis" post="[103]. The FDA approved these drugs for â€œemergency useâ€�"/>
  <result pre="evidence of it being a potent inhibitor of SARS coronavirus" exact="infection" post="and spread [104]. The data for the prevention and"/>
  <result pre="QTc syndrome, with increased risk of cardiac death, particularly in" exact="obesity" post="and diabetes, where ACE-2 is upregulated (Figure 7) due"/>
  <result pre="reduction in brown adipocytes. Polymorphism of CYP2D6 is higher in" exact="African" post="Americans and Asians [107,108,109], disproportionately affected by this disease."/>
  <result pre="Asians [107,108,109], disproportionately affected by this disease. One study in" exact="Lupus" post="patients in Korea showed significant variability in hydroxychloroquine levels"/>
  <result pre="levels due to CYP2D6 polymorphisms [110]. Another study in discoid" exact="lupus" post="found that 39% had either poor results from fast"/>
  <result pre="accounts of these genetic polymorphisms resulting in resistant strains of" exact="malaria" post="because of abnormalities in metabolism [112,113,114]. These same gene"/>
  <result pre="of abnormalities in metabolism [112,113,114]. These same gene polymorphisms affect" exact="heart" post="failure patients since the CYP 2D6 gene is responsible"/>
  <result pre="of care and patients were at higher risk of developing" exact="cardiac arrest" post="in the treatment group, especially when combined with Azithromycin"/>
  <result pre="transcription is affected by cytokines and glucocorticoids, downregulated by the" exact="acute" post="phase reactant IL-6 and upregulated by dexamethasone [122]. As"/>
  <result pre="concomitant use of steroids along with Remdesivir may lead to" exact="lower" post="drug levels of Remdesivir in COVID-19 patients with severe"/>
  <result pre="70 patients, the drug reportedly showed efficacy in treating the" exact="disease" post="with minimal adverse effects [126]. Another antiviral agent that"/>
  <result pre="found to reduce mortality rate and lead to a milder" exact="disease" post="course during the open clinical trial in the 2003"/>
  <result pre="been found to significantly reduce IL-6 and TNF-a with a" exact="lower" post="toxicity profile than Tocilizumab [136]. It has an excellent"/>
  <result pre="has an excellent safety profile, used extensively in triple negative" exact="breast cancer" post="and in human immunodeficiency virus (HIV) treatment [137,138]. There"/>
  <result pre="an excellent safety profile, used extensively in triple negative breast" exact="cancer" post="and in human immunodeficiency virus (HIV) treatment [137,138]. There"/>
  <result pre="used extensively in triple negative breast cancer and in human" exact="immunodeficiency" post="virus (HIV) treatment [137,138]. There is a granulocyte-macrophage colony-stimulating"/>
  <result pre="is being tested (Phase III clinical trial) for prevention of" exact="respiratory" post="failure and/or death in COVID-19 patients [139]. Convalescent plasma"/>
  <result pre="plasma has been administered to patients who are seropositive for" exact="acute" post="COVID-19 and hypoxic, which lead to undetectable viral load"/>
  <result pre="seropositive for acute COVID-19 and hypoxic, which lead to undetectable" exact="viral" post="load and improved oxygenation in 3 days after one"/>
  <result pre="non-intubated patients [140]. Convalescent plasma has been shown to reduce" exact="hypoxia" post="in intubated patients [140]. The adverse effects associated with"/>
  <result pre="[141]. Immunosuppression therapy is being examined to counteract the severe" exact="systemic" post="inflammatory reaction caused by SARS-COV-2 infection. One of the"/>
  <result pre="[143]. In the patients who were critically ill on ventilators" exact="secondary" post="to COVID-19, the treatment group showed a decrease in"/>
  <result pre="levels of HO-1 with heme arginate can improve inflammation and" exact="viral" post="infections [145,146,147,148]. Sickle cell patients, for example, are in"/>
  <result pre="of HO-1 with heme arginate can improve inflammation and viral" exact="infections" post="[145,146,147,148]. Sickle cell patients, for example, are in a"/>
  <result pre="[149]. HO-1 upregulation reduced oxidative stress in the kidney in" exact="sickle cell disease" post="[150]. Heme arginate, which is an upregulator of HO-1,"/>
  <result pre="upregulation reduced oxidative stress in the kidney in sickle cell" exact="disease" post="[150]. Heme arginate, which is an upregulator of HO-1,"/>
  <result pre="while increasing the ability of ferritin to chelate iron [150]." exact="Increased" post="levels of HO-1 play an essential role in the"/>
  <result pre="requires decreased adhesion, increased levels of antioxidants, and inhibition of" exact="viral" post="transcriptase enzymes, all of which was accomplished by administration"/>
  <result pre="the EBOLA virus (EBOV) transcription/replication leading to a decrease in" exact="viral" post="particles [148]. Heme arginate is well known to decrease"/>
  <result pre="decrease heme production and has been used extensively to treat" exact="porphyria" post="patients. The resultant increase in HO-1 reduces vasoconstriction [154,155],"/>
  <result pre="longer GT allele HO-1 polymorphism, abundant white adipose cells (in" exact="obesity" post="and diabetes), and those with CYP2D6 polymorphisms that lead"/>
  <result pre="in combination with Omega-3 that was shown to protect against" exact="obesity" post="induced oxidative stress, improve insulin sensitivity and convert white"/>
  <result pre="white fat to beige fat in a murine model of" exact="obesity" post="[157]. In addition, pomegranate seed oil upregulated HO-1, improved"/>
  <result pre="function, and attenuated hepatic steatosis/fibrosis in a murine model of" exact="obesity" post="[158]. It has previously been reported that HO-1 was"/>
  <result pre="and is upregulated in adipocytes in obesity, while adipocyte angiotensin" exact="deficiency" post="can prevent hypertension in the obese populations [160,161,162]. The"/>
  <result pre="in adipocytes in obesity, while adipocyte angiotensin deficiency can prevent" exact="hypertension" post="in the obese populations [160,161,162]. The major role of"/>
  <result pre="(ANG-II) to angiotensin 1-7 (AT 1-7) (Figure 8). ANG-II promotes" exact="obesity" post="associated metabolic diseases, oxidative stress, and inflammation in the"/>
  <result pre="angiotensin 1-7 (AT 1-7) (Figure 8). ANG-II promotes obesity associated" exact="metabolic diseases," post="oxidative stress, and inflammation in the lungs, vascular endothelial"/>
  <result pre="associated metabolic diseases, oxidative stress, and inflammation in the lungs," exact="vascular" post="endothelial cells, and kidney epithelial cells [159,163]. In contrast,"/>
  <result pre="and inflammation in the lungs, vascular endothelial cells, and kidney" exact="epithelial" post="cells [159,163]. In contrast, AT 1-7 promoted cardiovascular (CVS)"/>
  <result pre="and kidney epithelial cells [159,163]. In contrast, AT 1-7 promoted" exact="cardiovascular" post="(CVS) protection along with anti-inflammation, anti-proliferation, and anti-fibrosis in"/>
  <result pre="in adipocytes [164,165]. ACE-2 is upregulated in adipose tissue in" exact="obesity" post="and diabetes, with an increase in the ACE-2 receptors"/>
  <result pre="a major increase in the number of white adipocytes in" exact="obesity" post="accounts for the increase in total ACE-2 receptors [163]."/>
  <result pre="of white adipocytes in obesity accounts for the increase in" exact="total" post="ACE-2 receptors [163]. Since the spike protein of the"/>
  <result pre="ACE levels are at higher risk of developing severe inflammation" exact="secondary" post="to COVID-19 infection [166] (Figure 8). 12. Conclusions The"/>
  <result pre="at higher risk of developing severe inflammation secondary to COVID-19" exact="infection" post="[166] (Figure 8). 12. Conclusions The main drugs currently"/>
  <result pre="dual drug-therapy to counteract the severe inflammation caused by COVID-19." exact="Obesity" post="is a chronic inflammatory disease manifested by an increase"/>
  <result pre="counteract the severe inflammation caused by COVID-19. Obesity is a" exact="chronic" post="inflammatory disease manifested by an increase in cytokine levels"/>
  <result pre="severe inflammation caused by COVID-19. Obesity is a chronic inflammatory" exact="disease" post="manifested by an increase in cytokine levels at baseline,"/>
  <result pre="white necrotic adipocytes and have many more white adipocytes in" exact="total" post="than the number of brown adipocytes of their lean"/>
  <result pre="of brown adipocytes of their lean counterparts. COVID-19 causes severe" exact="systemic" post="inflammation and downregulation of HO-1, already downregulated in the"/>
  <result pre="systemic inflammation and downregulation of HO-1, already downregulated in the" exact="chronic" post="inflammatory state of obesity. The clinical course of the"/>
  <result pre="chronic inflammatory state of obesity. The clinical course of the" exact="disease" post="has been challenged by the interaction of three genetic"/>
  <result pre="enzyme systems. Effective therapy must include anti-viral drugs to halt" exact="viral" post="replication. The second must involve the upregulation of the"/>
  <result pre="Abbreviations ACE angiotensin converting enzyme HO heme oxygenase HIV human" exact="immunodeficiency" post="virus SARS acute respiratory distress syndrome MERS middle East"/>
  <result pre="converting enzyme HO heme oxygenase HIV human immunodeficiency virus SARS" exact="acute" post="respiratory distress syndrome MERS middle East respiratory syndrome ROS"/>
  <result pre="enzyme HO heme oxygenase HIV human immunodeficiency virus SARS acute" exact="respiratory" post="distress syndrome MERS middle East respiratory syndrome ROS reactive"/>
  <result pre="heme oxygenase HIV human immunodeficiency virus SARS acute respiratory distress" exact="syndrome" post="MERS middle East respiratory syndrome ROS reactive oxygen species"/>
  <result pre="immunodeficiency virus SARS acute respiratory distress syndrome MERS middle East" exact="respiratory" post="syndrome ROS reactive oxygen species NO nitric oxide cAMP"/>
  <result pre="virus SARS acute respiratory distress syndrome MERS middle East respiratory" exact="syndrome" post="ROS reactive oxygen species NO nitric oxide cAMP cyclic"/>
  <result pre="ALA delta-aminolevulinic acid HMB hydroxymethylbilane ETC electron transport chain AKI" exact="acute" post="kidney injury ARF acute renal failure CHF congestive heart"/>
  <result pre="delta-aminolevulinic acid HMB hydroxymethylbilane ETC electron transport chain AKI acute" exact="kidney injury" post="ARF acute renal failure CHF congestive heart failure AOCI"/>
  <result pre="hydroxymethylbilane ETC electron transport chain AKI acute kidney injury ARF" exact="acute" post="renal failure CHF congestive heart failure AOCI anemia of"/>
  <result pre="ETC electron transport chain AKI acute kidney injury ARF acute" exact="renal failure" post="CHF congestive heart failure AOCI anemia of chronic inflammation"/>
  <result pre="chain AKI acute kidney injury ARF acute renal failure CHF" exact="congestive heart failure" post="AOCI anemia of chronic inflammation Ox-HDL oxidized high-density lipoprotein"/>
  <result pre="AKI acute kidney injury ARF acute renal failure CHF congestive" exact="heart" post="failure AOCI anemia of chronic inflammation Ox-HDL oxidized high-density"/>
  <result pre="injury ARF acute renal failure CHF congestive heart failure AOCI" exact="anemia" post="of chronic inflammation Ox-HDL oxidized high-density lipoprotein VLDL very"/>
  <result pre="acute renal failure CHF congestive heart failure AOCI anemia of" exact="chronic" post="inflammation Ox-HDL oxidized high-density lipoprotein VLDL very low-density lipoprotein"/>
  <result pre="oxidized high-density lipoprotein VLDL very low-density lipoprotein IL interleukins TNF" exact="tumor" post="necrosis factor NADH nicotinamide adenine dinucleotide FADH2 flavin adenine"/>
  <result pre="Mechanisms of COVID-19 Pathways: Focus on Hemostasis, Hemotransfusion Issues and" exact="Blood" post="gas ExchangeKardiologiia20206091910.18087/cardio.2020.5.n113232515699 5.ReadR.Flawed methods in COVID-19: Attacks the 1-Beta"/>
  <result pre="Inhibit Human Heme MetabolismChemRxiv202010.26434/chemrxiv.11938173.v5 8.GrossS.JahnC.CushmanS.BarC.ThumT.SARS-CoV-2 receptor ACE2-dependent implications on the" exact="cardiovascular" post="system: From basic science to clinical implicationsJ. Mol. Cell."/>
  <result pre="science to clinical implicationsJ. Mol. Cell. Cardiol.2020144475310.1016/j.yjmcc.2020.04.03132360703 9.MartinezJ.C.GarciaH.O.OtheguyL.E.DrummondG.S.KappasA.Control of severe" exact="hyperbilirubinemia" post="in full-term newborns with the inhibitor bilirubin production Sn-mesoporphrinPediatrics19991031510.1542/peds.103.1.19917431"/>
  <result pre="vivo heme catabolismArch. Biochem. Biophys.1987255647410.1016/0003-9861(87)90294-33592668 12.DrummondG.S.KappasA.Sn-protoporphyrin inhibition of fetal and" exact="neonatal" post="brain heme oxygenase. Transplacental passage of the metalloporphyrin and"/>
  <result pre="heme catabolismArch. Biochem. Biophys.1987255647410.1016/0003-9861(87)90294-33592668 12.DrummondG.S.KappasA.Sn-protoporphyrin inhibition of fetal and neonatal" exact="brain" post="heme oxygenase. Transplacental passage of the metalloporphyrin and prenatal"/>
  <result pre="oxygenase. Transplacental passage of the metalloporphyrin and prenatal suppression of" exact="hyperbilirubinemia" post="in the newborn animalJ. Clin. Investig.19867797197610.1172/JCI1123983753986 13.SissonT.R.DrummondG.S.SamonteD.CalabioR.KappasA.Sn-protoporphyrin blocks the"/>
  <result pre="develops postnatally in homozygous Gunn ratsJ. Exp. Med.19881671247125210.1084/jem.167.3.12473127524 14.ValaesT.DrummondG.S.KappasA.Control of" exact="hyperbilirubinemia" post="in glucose-6-phosphate dehydrogenase-deficient newborns using an inhibitor of bilirubin"/>
  <result pre="Sci. USA19686174875510.1073/pnas.61.2.7484386763 17.HooperP.L.COVID-19 and heme oxygenase: Novel insight into the" exact="disease" post="and potential therapiesCell Stress Chaperones202010.1007/s12192-020-01126-9 18.FullerS.J.WileyJ.S.Heme Biosynthesis and Its"/>
  <result pre="therapiesCell Stress Chaperones202010.1007/s12192-020-01126-9 18.FullerS.J.WileyJ.S.Heme Biosynthesis and Its Disorders: Porphyrias and" exact="Sideroblastic" post="AnemiasHematology Basic Principles and Practice7th ed.RonaldH.LeslieE.HelenE.JeffreyI.JohnA.Elsevier Health SciencesNew York,"/>
  <result pre="USA199794109251093010.1073/pnas.94.20.109259380736 22.TraczM.J.JuncosJ.P.CroattA.J.AckermanA.W.GrandeJ.P.KnutsonK.L.KaneG.C.TerzicA.GriffinM.D.NathK.A.Deficiency of heme oxygenase-1 impairs renal hemodynamics and exaggerates" exact="systemic" post="inflammatory responses to renal ischemiaKidney Int.2007721073108010.1038/sj.ki.500247117728706 23.KawashimaA.OdaY.YachieA.KoizumiS.NakanishiI.Heme oxygenase-1 deficiency:"/>
  <result pre="a cardinal pathologic feature in human heme oxygenase-1 deficiencyAm. J." exact="Kidney" post="Dis.20003586387010.1016/S0272-6386(00)70256-310793020 25.KartikasariA.E.WagenerF.A.YachieA.WiegerinckE.T.KemnaE.H.SwinkelsD.W.Hepcidin suppression and defective iron recycling account for"/>
  <result pre="in heme oxygenase-1 deficiencyJ. Cell. Mol. Med.2009133091310210.1111/j.1582-4934.2008.00494.x18774956 26.RadhakrishnanN.YadavS.P.SachdevaA.PruthiP.K.SawhneyS.PiplaniT.WadaT.YachieA.Human heme oxygenase-1" exact="deficiency" post="presenting with hemolysis, nephritis, and aspleniaJ. Pediatr. Hematol. Oncol.201133747810.1097/MPH.0b013e3181fd2aae21088618"/>
  <result pre="Clinical Significance: A ReviewCurr. Drug Targets201819385410.2174/138945011866617012514455728124606 29.CavezziA.TroianiE.CorraoS.COVID-19: Hemoglobin, iron, and" exact="hypoxia" post="beyond inflammation. A narrative reviewClin. Pract.202010127110.4081/cp.2020.127132509258 30.YachieA.NiidaY.WadaT.IgarashiN.KanedaH.TomaT.OhtaK.KasaharaY.KoizumiS.Oxidative stress causes"/>
  <result pre="heme oxygenase-1 deficiencyJ. Clin. Investig.199910312913510.1172/JCI41659884342 31.ZhangQ.ShanK.S.MinalyanA.Oâ€™SullivanC.NaceT.A Rare Presentation of Coronavirus" exact="Disease" post="2019 (COVID-19) Induced Viral Myositis with Subsequent RhabdomyolysisCureus202012e807410.7759/cureus.807432542129 32.ChanK.H.FaroujiI.Abu"/>
  <result pre="Investig.199910312913510.1172/JCI41659884342 31.ZhangQ.ShanK.S.MinalyanA.Oâ€™SullivanC.NaceT.A Rare Presentation of Coronavirus Disease 2019 (COVID-19) Induced" exact="Viral" post="Myositis with Subsequent RhabdomyolysisCureus202012e807410.7759/cureus.807432542129 32.ChanK.H.FaroujiI.Abu HanoudA.SlimJ.Weakness and elevated creatinine"/>
  <result pre="and elevated creatinine kinase as the initial presentation of coronavirus" exact="disease" post="2019 (COVID-19)Am. J. Emerg. Med.2020381548.e11548.e310.1016/j.ajem.2020.05.01532414522 33.SamiesN.L.PinnintiS.JamesS.H.Rhabdomyolysis and Acute Renal"/>
  <result pre="of coronavirus disease 2019 (COVID-19)Am. J. Emerg. Med.2020381548.e11548.e310.1016/j.ajem.2020.05.01532414522 33.SamiesN.L.PinnintiS.JamesS.H.Rhabdomyolysis and" exact="Acute" post="Renal Failure in an Adolescent with COVID-19J. Pediatric Infect."/>
  <result pre="coronavirus disease 2019 (COVID-19)Am. J. Emerg. Med.2020381548.e11548.e310.1016/j.ajem.2020.05.01532414522 33.SamiesN.L.PinnintiS.JamesS.H.Rhabdomyolysis and Acute" exact="Renal" post="Failure in an Adolescent with COVID-19J. Pediatric Infect. Dis."/>
  <result pre="disease 2019 (COVID-19)Am. J. Emerg. Med.2020381548.e11548.e310.1016/j.ajem.2020.05.01532414522 33.SamiesN.L.PinnintiS.JamesS.H.Rhabdomyolysis and Acute Renal" exact="Failure" post="in an Adolescent with COVID-19J. Pediatric Infect. Dis. Soc.202010.1093/jpids/piaa083"/>
  <result pre="33.SamiesN.L.PinnintiS.JamesS.H.Rhabdomyolysis and Acute Renal Failure in an Adolescent with COVID-19J." exact="Pediatric" post="Infect. Dis. Soc.202010.1093/jpids/piaa083 34.Valente-AcostaB.Moreno-SanchezF.Fueyo-RodriguezO.Palomar-LeverA.Rhabdomyolysis as an initial presentation in"/>
  <result pre="35.NathK.A.BallaG.VercellottiG.M.BallaJ.JacobH.S.LevittM.D.RosenbergM.E.Induction of heme oxygenase is a rapid, protective response in" exact="rhabdomyolysis" post="in the ratJ. Clin. Investig.19929026727010.1172/JCI1158471634613 36.Gonzalez-MichacaL.FarrugiaG.CroattA.J.AlamJ.NathK.A.Heme: A determinant of"/>
  <result pre="Clin. Investig.19929026727010.1172/JCI1158471634613 36.Gonzalez-MichacaL.FarrugiaG.CroattA.J.AlamJ.NathK.A.Heme: A determinant of life and death in" exact="renal tubular" post="epithelial cellsAm. J. Physiol. Ren. Physiol.2004286F370F37710.1152/ajprenal.00300.200314707007 37.BallaJ.JacobH.S.BallaG.NathK.EatonJ.W.VercellottiG.M.Endothelial-cell heme uptake"/>
  <result pre="36.Gonzalez-MichacaL.FarrugiaG.CroattA.J.AlamJ.NathK.A.Heme: A determinant of life and death in renal tubular" exact="epithelial" post="cellsAm. J. Physiol. Ren. Physiol.2004286F370F37710.1152/ajprenal.00300.200314707007 37.BallaJ.JacobH.S.BallaG.NathK.EatonJ.W.VercellottiG.M.Endothelial-cell heme uptake from"/>
  <result pre="in spontaneously breathing patients with COVID-19medRxiv202010.1101/2020.03.10.20033522 40.HedenstiernaG.ChenL.HedenstiernaM.LiebermanR.FineD.H.Nitric oxide dosed in" exact="short" post="bursts at high concentrations may protect against Covid 19Nitric"/>
  <result pre="concentrations may protect against Covid 19Nitric Oxide20201031310.1016/j.niox.2020.06.00532590117 41.FangL.KarakiulakisG.RothM.Are patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?Lancet"/>
  <result pre="protect against Covid 19Nitric Oxide20201031310.1016/j.niox.2020.06.00532590117 41.FangL.KarakiulakisG.RothM.Are patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?Lancet Respir. Med.20208e2110.1016/S2213-2600(20)30116-832171062 42.MountP.F.PowerD.A.Nitric"/>
  <result pre="and regulation of synthesisActa Physiol. (Oxf.)200618743344610.1111/j.1748-1716.2006.01582.x16866775 43.SzilagyiJ.T.MishinV.HeckD.E.JanY.H.AleksunesL.M.RichardsonJ.R.HeindelN.D.LaskinD.L.LaskinJ.D.Selective Targeting of Heme" exact="Protein" post="in Cytochrome P450 and Nitric Oxide Synthase by DiphenyleneiodoniumToxicol."/>
  <result pre="al.Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with progressive" exact="atherosclerosis" post="and incident cardiovascular diseaseArterioscler. Thromb. Vasc. Biol.20153522923610.1161/ATVBAHA.114.30472925359861 47.YamadaN.YamayaM.OkinagaS.NakayamaK.SekizawaK.ShibaharaS.SasakiH.Microsatellite polymorphism"/>
  <result pre="promoter microsatellite polymorphism is associated with progressive atherosclerosis and incident" exact="cardiovascular" post="diseaseArterioscler. Thromb. Vasc. Biol.20153522923610.1161/ATVBAHA.114.30472925359861 47.YamadaN.YamayaM.OkinagaS.NakayamaK.SekizawaK.ShibaharaS.SasakiH.Microsatellite polymorphism in the heme"/>
  <result pre="polymorphism in the heme oxygenase-1 gene promoter is associated with" exact="susceptibility to" post="emphysemaAm. J. Hum. Genet.20006618719510.1086/30272910631150 48.OkamotoI.KroglerJ.EndlerG.KaufmannS.MustafaS.ExnerM.MannhalterC.WagnerO.PehambergerH.A microsatellite polymorphism in the"/>
  <result pre="49.HiraiH.KuboH.YamayaM.NakayamaK.NumasakiM.KobayashiS.SuzukiS.ShibaharaS.SasakiH.Microsatellite polymorphism in heme oxygenase-1 gene promoter is associated with" exact="susceptibility to" post="oxidant-induced apoptosis in lymphoblastoid cell linesBlood20031021619162110.1182/blood-2002-12-373312730098 50.GuenegouA.LeynaertB.BenessianoJ.PinI.DemolyP.NeukirchF.BoczkowskiJ.AubierM.Association of lung"/>
  <result pre="in a general population sample. Results from the European Community" exact="Respiratory" post="Health Survey (ECRHS), FranceJ. Med. Genet.200643e4310.1136/jmg.2005.03974316882737 51.ExnerM.SchillingerM.MinarE.MlekuschW.SchlerkaG.HaumerM.MannhalterC.WagnerO.Heme oxygenase-1 gene"/>
  <result pre="Endovasc. Ther.2001843344010.1177/15266028010080050111718398 52.BaoW.SongF.LiX.RongS.YangW.WangD.XuJ.FuJ.ZhaoY.LiuL.Association between heme oxygenase-1 gene promoter polymorphisms and" exact="type 2" post="diabetes mellitus: A HuGE review and meta-analysisAm. J. Epidemiol.201017263163610.1093/aje/kwq16220682519"/>
  <result pre="52.BaoW.SongF.LiX.RongS.YangW.WangD.XuJ.FuJ.ZhaoY.LiuL.Association between heme oxygenase-1 gene promoter polymorphisms and type 2" exact="diabetes" post="mellitus: A HuGE review and meta-analysisAm. J. Epidemiol.201017263163610.1093/aje/kwq16220682519 53.ChoiS.W.YeungV.T.BenzieI.F.Heme"/>
  <result pre="microsatellite polymorphism, oxidative stress, glycemic control, and complication development in" exact="type 2" post="diabetes patientsFree Radic. Biol. Med.201253606310.1016/j.freeradbiomed.2012.04.01722583702 54.EndlerG.ExnerM.SchillingerM.MarculescuR.Sunder-PlassmannR.RaithM.JordanovaN.WojtaJ.MannhalterC.WagnerO.F.et al.A microsatellite polymorphism"/>
  <result pre="oxidative stress, glycemic control, and complication development in type 2" exact="diabetes" post="patientsFree Radic. Biol. Med.201253606310.1016/j.freeradbiomed.2012.04.01722583702 54.EndlerG.ExnerM.SchillingerM.MarculescuR.Sunder-PlassmannR.RaithM.JordanovaN.WojtaJ.MannhalterC.WagnerO.F.et al.A microsatellite polymorphism in"/>
  <result pre="coronary artery diseaseThromb. Haemost.20049115516110.1111/j.1538-7836.2003.tb03344.x14691581 55.AbrahamN.G.JungeJ.M.DrummondG.S.Translational Significance of Heme Oxygenase in" exact="Obesity" post="and Metabolic SyndromeTrends Pharmacol. Sci.201637173610.1016/j.tips.2015.09.00326515032 56.VitekL.JirsaM.BrodanovaM.KalabM.MarecekZ.DanzigV.NovotnyL.KotalP.Gilbert syndrome and ischemic"/>
  <result pre="Heme Oxygenase in Obesity and Metabolic SyndromeTrends Pharmacol. Sci.201637173610.1016/j.tips.2015.09.00326515032 56.VitekL.JirsaM.BrodanovaM.KalabM.MarecekZ.DanzigV.NovotnyL.KotalP.Gilbert" exact="syndrome" post="and ischemic heart disease: A protective effect of elevated"/>
  <result pre="Obesity and Metabolic SyndromeTrends Pharmacol. Sci.201637173610.1016/j.tips.2015.09.00326515032 56.VitekL.JirsaM.BrodanovaM.KalabM.MarecekZ.DanzigV.NovotnyL.KotalP.Gilbert syndrome and ischemic" exact="heart" post="disease: A protective effect of elevated bilirubin levelsAtherosclerosis200216044945610.1016/S0021-9150(01)00601-311849670 57.KalousovaM.NovotnyL.ZimaT.BraunM.VitekL.Decreased"/>
  <result pre="leptin resistanceFront. Med.2013720722210.1007/s11684-013-0263-523580174 60.PetersonS.J.DaveN.KothariJ.The Effects of Heme Oxygenase Upregulation on" exact="Obesity" post="and the Metabolic SyndromeAntioxid. Redox Signal.2020321061107010.1089/ars.2019.795431880952 61.ZhangY.ScarpaceP.J.The role of"/>
  <result pre="and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves" exact="vascular" post="reactivity in rat model of diabetesCirculation20051113126313410.1161/CIRCULATIONAHA.104.51710215939814 68.SinghS.McClungJ.ThompsonE.GlickY.GreenbergM.Acosta-BaezG.EdrisB.ShapiroJ.AbrahamN.G.Cardioprotective heme oxygenase-1-PGC-1Î±"/>
  <result pre="of diabetesCirculation20051113126313410.1161/CIRCULATIONAHA.104.51710215939814 68.SinghS.McClungJ.ThompsonE.GlickY.GreenbergM.Acosta-BaezG.EdrisB.ShapiroJ.AbrahamN.G.Cardioprotective heme oxygenase-1-PGC-1Î± signaling in epicardial fat attenuates" exact="cardiovascular" post="risk in humans as in obese miceObesity (Silver Spring)201910.1002/oby.22608"/>
  <result pre="Spring)2019271560156110.1002/oby.2262931498551 70.PetersonS.J.RubinsteinR.FaroquiM.RazaA.BoumazaI.ZhangY.StecD.AbrahamN.G.Positive Effects of Heme Oxygenase Upregulation on Adiposity and" exact="Vascular" post="Dysfunction: Gene Targeting vs. Pharmacologic TherapyInt. J. Mol. Sci.201920251410.3390/ijms20102514"/>
  <result pre="Biological Processes in Physiology and DiseasesCells2019879510.3390/cells8080795 79.BerryB.J.TrewinA.J.AmitranoA.M.KimM.WojtovichA.P.Use the Protonmotive Force:" exact="Mitochondrial" post="Uncoupling and Reactive Oxygen SpeciesJ. Mol. Biol.20184303873389110.1016/j.jmb.2018.03.02529626541 80.SinghS.P.SchragenheimJ.CaoJ.FalckJ.R.AbrahamN.G.BellnerL.PGC-1 alpha"/>
  <result pre="Lipid Mediat.201612581810.1016/j.prostaglandins.2016.07.00427418542 81.SchragenheimJ.MaayanO.AbrahamN.G.Chapter 4: HO-1-derived CO Is a Regulator of" exact="Vascular" post="Function and Metabolic SyndromeRSC Metallobiology20185910010.1039/9781788013000-00059 82.StuartJ.A.BrindleK.M.HarperJ.A.BrandM.D.Mitochondrial proton leak and"/>
  <result pre="in hepatic diseaseAm. J. Physiol. Gastrointest. Liver Physiol.2018314G668G67610.1152/ajpgi.00026.201829494209 89.HindsT.D.Jr.HosickP.A.ChenS.TukeyR.H.HankinsM.W.Nestor-KalinoskiA.StecD.E.Mice with" exact="hyperbilirubinemia" post="due to Gilbertâ€™s syndrome polymorphism are resistant to hepatic"/>
  <result pre="Physiol. Gastrointest. Liver Physiol.2018314G668G67610.1152/ajpgi.00026.201829494209 89.HindsT.D.Jr.HosickP.A.ChenS.TukeyR.H.HankinsM.W.Nestor-KalinoskiA.StecD.E.Mice with hyperbilirubinemia due to Gilbertâ€™s" exact="syndrome" post="polymorphism are resistant to hepatic steatosis by decreased serine"/>
  <result pre="with hyperbilirubinemia due to Gilbertâ€™s syndrome polymorphism are resistant to" exact="hepatic steatosis" post="by decreased serine 73 phosphorylation of PPARalphaAm. J. Physiol."/>
  <result pre="HO-1 Gene Therapy is Effective in Antioxidant Treatment of Insulin" exact="Resistance" post="and Vascular Function in an Obese Mice ModelAntioxidants202094010.3390/antiox9010040 91.WaldmanM.BellnerL.VanellaL.SchragenheimJ.SodhiK.SinghS.P.LinD.LakhkarA.LiJ.HochhauserE.et"/>
  <result pre="Therapy is Effective in Antioxidant Treatment of Insulin Resistance and" exact="Vascular" post="Function in an Obese Mice ModelAntioxidants202094010.3390/antiox9010040 91.WaldmanM.BellnerL.VanellaL.SchragenheimJ.SodhiK.SinghS.P.LinD.LakhkarA.LiJ.HochhauserE.et al.Epoxyeicosatrienoic Acids"/>
  <result pre="Obese Mice ModelAntioxidants202094010.3390/antiox9010040 91.WaldmanM.BellnerL.VanellaL.SchragenheimJ.SodhiK.SinghS.P.LinD.LakhkarA.LiJ.HochhauserE.et al.Epoxyeicosatrienoic Acids Regulate Adipocyte Differentiation of" exact="Mouse" post="3T3 Cells, Via PGC-1alpha Activation, Which Is Required for"/>
  <result pre="Via PGC-1alpha Activation, Which Is Required for HO-1 Expression and" exact="Increased" post="Mitochondrial FunctionStem Cells Dev.2016251084109410.1089/scd.2016.007227224420 92.ZhuJ.JiP.PangJ.ZhongZ.LiH.HeC.ZhangJ.ZhaoC.Clinical characteristics of 3062 COVID-19"/>
  <result pre="PGC-1alpha Activation, Which Is Required for HO-1 Expression and Increased" exact="Mitochondrial" post="FunctionStem Cells Dev.2016251084109410.1089/scd.2016.007227224420 92.ZhuJ.JiP.PangJ.ZhongZ.LiH.HeC.ZhangJ.ZhaoC.Clinical characteristics of 3062 COVID-19 patients:"/>
  <result pre="meta-analysisJ. Med. Virol.202010.1002/jmv.25884 93.SlaatsJ.Ten OeverJ.van de VeerdonkF.L.NeteaM.G.IL-1beta/IL-6/CRP and IL-18/ferritin: Distinct" exact="Inflammatory" post="Programs in InfectionsPLoS Pathog.201612e100597310.1371/journal.ppat.100597327977798 94.PulivarthiS.GurramM.K.Effectiveness of d-dimer as a"/>
  <result pre="al.Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected" exact="Pneumonia" post="in Wuhan, ChinaJAMA202010.1001/jama.2020.1585 103.SavarinoA.Di TraniL.DonatelliI.CaudaR.CassoneA.New insights into the antiviral"/>
  <result pre="Infect. Dis.20066676910.1016/S1473-3099(06)70361-916439323 104.VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 105.Ingelman-SundbergM.Genetic polymorphisms of cytochrome P450 2D6"/>
  <result pre="CaliforniaPharmacogenetics20011148949910.1097/00008571-200108000-0000411505219 108.YeeM.M.JosephsonC.HillC.E.HarringtonR.CastillejoM.I.RamjitR.OsunkwoI.Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in" exact="African" post="American children with sickle cell diseaseJ. Pediatr. Hematol. Oncol.201335e301e30510.1097/MPH.0b013e31828e52d223619115"/>
  <result pre="108.YeeM.M.JosephsonC.HillC.E.HarringtonR.CastillejoM.I.RamjitR.OsunkwoI.Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African" exact="American" post="children with sickle cell diseaseJ. Pediatr. Hematol. Oncol.201335e301e30510.1097/MPH.0b013e31828e52d223619115 109.GaedigkA.BhathenaA.NdjountcheL.PearceR.E.Abdel-RahmanS.M.AlanderS.W.BradfordL.D.RoganP.K.LeederJ.S.Identification"/>
  <result pre="novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in" exact="African" post="AmericansPharmacogenomics J.2005517318210.1038/sj.tpj.650030515768052 110.LeeJ.Y.VinayagamoorthyN.HanK.KwokS.K.JuJ.H.ParkK.S.JungS.H.ParkS.W.ChungY.J.ParkS.H.Association of Polymorphisms of Cytochrome P450 2D6"/>
  <result pre="AmericansPharmacogenomics J.2005517318210.1038/sj.tpj.650030515768052 110.LeeJ.Y.VinayagamoorthyN.HanK.KwokS.K.JuJ.H.ParkK.S.JungS.H.ParkS.W.ChungY.J.ParkS.H.Association of Polymorphisms of Cytochrome P450 2D6 with" exact="Blood" post="Hydroxychloroquine Levels in Patients with Systemic Lupus ErythematosusArthritis Rheumatol.20166818419010.1002/art.3940226316040"/>
  <result pre="Cytochrome P450 2D6 with Blood Hydroxychloroquine Levels in Patients with" exact="Systemic" post="Lupus ErythematosusArthritis Rheumatol.20166818419010.1002/art.3940226316040 111.WahieS.DalyA.K.CordellH.J.GoodfieldM.J.JonesS.K.LovellC.R.CarmichaelA.J.CarrM.M.DrummondA.NatarajanS.et al.Clinical and pharmacogenetic influences on"/>
  <result pre="P450 2D6 with Blood Hydroxychloroquine Levels in Patients with Systemic" exact="Lupus" post="ErythematosusArthritis Rheumatol.20166818419010.1002/art.3940226316040 111.WahieS.DalyA.K.CordellH.J.GoodfieldM.J.JonesS.K.LovellC.R.CarmichaelA.J.CarrM.M.DrummondA.NatarajanS.et al.Clinical and pharmacogenetic influences on response"/>
  <result pre="al.Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid" exact="lupus" post="erythematosus: A retrospective cohort studyJ. Investig. Dermatol.20111311981198610.1038/jid.2011.16721734714 112.HeX.PanM.ZengW.ZouC.PiL.QinY.ZhaoL.QinP.LuY.BairdJ.K.et al.Multiple"/>
  <result pre="A retrospective cohort studyJ. Investig. Dermatol.20111311981198610.1038/jid.2011.16721734714 112.HeX.PanM.ZengW.ZouC.PiL.QinY.ZhaoL.QinP.LuY.BairdJ.K.et al.Multiple relapses of" exact="Plasmodium vivax malaria" post="acquired from West Africa and association with poor metabolizer"/>
  <result pre="cohort studyJ. Investig. Dermatol.20111311981198610.1038/jid.2011.16721734714 112.HeX.PanM.ZengW.ZouC.PiL.QinY.ZhaoL.QinP.LuY.BairdJ.K.et al.Multiple relapses of Plasmodium vivax" exact="malaria" post="acquired from West Africa and association with poor metabolizer"/>
  <result pre="studyJ. Investig. Dermatol.20111311981198610.1038/jid.2011.16721734714 112.HeX.PanM.ZengW.ZouC.PiL.QinY.ZhaoL.QinP.LuY.BairdJ.K.et al.Multiple relapses of Plasmodium vivax malaria" exact="acquired" post="from West Africa and association with poor metabolizer CYP2D6"/>
  <result pre="human cytochrome P450 2D6 enzymeDrug Metab. Rev.20094157364310.1080/0360253090311872919645588 116.MottetF.VardenyO.de DenusS.Pharmacogenomics of" exact="heart" post="failure: A systematic reviewPharmacogenomics2016171817185810.2217/pgs-2016-011827813451 117.QaseemA.YostJ.Etxeandia-IkobaltzetaI.MillerM.C.AbrahamG.M.ObleyA.J.ForcieaM.A.JokelaJ.A.HumphreyL.L.Should Clinicians Use Chloroquine or"/>
  <result pre="in Hospitalized Patients with Covid-19N. Engl. J. Med.20203822411241810.1056/NEJMoa201241032379955 119.AgostiniM.L.AndresE.L.SimsA.C.GrahamR.L.SheahanT.P.LuX.SmithE.C.CaseJ.B.FengJ.Y.JordanR.et al.Coronavirus" exact="Susceptibility to" post="the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral"/>
  <result pre="Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the" exact="Viral" post="Polymerase and the Proofreading ExoribonucleasemBio2018910.1128/mBio.00221-1829511076 120.SheahanT.P.SimsA.C.LeistS.R.SchaferA.WonJ.BrownA.J.MontgomeryS.A.HoggA.BabusisD.ClarkeM.O.et al.Comparative therapeutic efficacy"/>
  <result pre="gene variants of CYP3A4Clin. Pharmacol. Ther.20149634034810.1038/clpt.2014.12924926778 123.WangY.ZhangD.DuG.Remdesivir in Adults with" exact="Severe" post="COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Multicenter TrialLancet20203951569157810.1016/S0140-6736(20)31022-932423584 124.DuY.X.ChenX.P.Favipiravir: Pharmacokinetics"/>
  <result pre="We Stand Now?Iran. J. Med. Sci.202045818210.30476/ijms.2020.4635732210483 127.YazdanpanahY.GueryB.Antiretroviral drugs in severe" exact="acute" post="respiratory syndromePresse Med.20063510510710.1016/S0755-4982(06)74531-616462674 128.HuiD.S.WongG.W.Advancements in the battle against severe"/>
  <result pre="Stand Now?Iran. J. Med. Sci.202045818210.30476/ijms.2020.4635732210483 127.YazdanpanahY.GueryB.Antiretroviral drugs in severe acute" exact="respiratory" post="syndromePresse Med.20063510510710.1016/S0755-4982(06)74531-616462674 128.HuiD.S.WongG.W.Advancements in the battle against severe acute"/>
  <result pre="acute respiratory syndromePresse Med.20063510510710.1016/S0755-4982(06)74531-616462674 128.HuiD.S.WongG.W.Advancements in the battle against severe" exact="acute" post="respiratory syndromeExpert Opin. Pharmacother.200451687169310.1517/14656566.5.8.168715264983 129.CaoB.WangY.WenD.LiuW.WangJ.FanG.RuanL.SongB.CaiY.WeiM.et al.A Trial of Lopinavir-Ritonavir"/>
  <result pre="respiratory syndromePresse Med.20063510510710.1016/S0755-4982(06)74531-616462674 128.HuiD.S.WongG.W.Advancements in the battle against severe acute" exact="respiratory" post="syndromeExpert Opin. Pharmacother.200451687169310.1517/14656566.5.8.168715264983 129.CaoB.WangY.WenD.LiuW.WangJ.FanG.RuanL.SongB.CaiY.WeiM.et al.A Trial of Lopinavir-Ritonavir in"/>
  <result pre="Pharmacother.200451687169310.1517/14656566.5.8.168715264983 129.CaoB.WangY.WenD.LiuW.WangJ.FanG.RuanL.SongB.CaiY.WeiM.et al.A Trial of Lopinavir-Ritonavir in Adults Hospitalized with" exact="Severe" post="Covid-19N. Engl. J. Med.20203821787179910.1056/NEJMoa200128232187464 130.CNC.C.Kaletra Capsules and Oral SolutionAvailable"/>
  <result pre="on 30 June 2020) 131.MartinezM.A.Compounds with Therapeutic Potential against Novel" exact="Respiratory" post="2019 CoronavirusAntimicrob. Agents Chemother.20206410.1128/AAC.00399-20 132.FuB.XuX.WeiH.Why tocilizumab could be an"/>
  <result pre="release syndromeExpert Rev. Clin. Immunol.20191581382210.1080/1744666X.2019.162990431219357 137.JiaoX.NawabO.PatelT.KossenkovA.V.HalamaN.JaegerD.PestellR.G.Recent Advances Targeting CCR5 for" exact="Cancer" post="and Its Role in Immuno-OncologyCancer Res.2019794801480710.1158/0008-5472.CAN-19-116731292161 138.LedermanM.M.Penn-NicholsonA.ChoM.MosierD.Biology of CCR5"/>
  <result pre="in Immuno-OncologyCancer Res.2019794801480710.1158/0008-5472.CAN-19-116731292161 138.LedermanM.M.Penn-NicholsonA.ChoM.MosierD.Biology of CCR5 and its role in" exact="HIV infection" post="and treatmentJAMA200629681582610.1001/jama.296.7.81516905787 139.ZhaoM.Cytokine storm and immunomodulatory therapy in COVID-19:"/>
  <result pre="Immuno-OncologyCancer Res.2019794801480710.1158/0008-5472.CAN-19-116731292161 138.LedermanM.M.Penn-NicholsonA.ChoM.MosierD.Biology of CCR5 and its role in HIV" exact="infection" post="and treatmentJAMA200629681582610.1001/jama.296.7.81516905787 139.ZhaoM.Cytokine storm and immunomodulatory therapy in COVID-19:"/>
  <result pre="postischemic reperfusion liver damage: Effect of L-arginineMicrosurgery200626253210.1002/micr.2020616444720 145.StaudingerR.AbrahamN.G.LevereR.D.KappasA.Inhibition of human" exact="immunodeficiency" post="virus-1 reverse transcriptase by heme and synthetic heme analogsProc."/>
  <result pre="Protective role of heme and IL-1Exp. Hematol.1993212632687678812 147.LevereR.D.GongY.F.KappasA.BucherD.J.WormserG.P.AbrahamN.G.Heme inhibits human" exact="immunodeficiency" post="virus 1 replication in cell cultures and enhances the"/>
  <result pre="human kidneyKidney Int.199037949910.1038/ki.1990.132105407 155.SacerdotiD.EscalanteB.AbrahamN.G.McGiffJ.C.LevereR.D.SchwartzmanM.L.Treatment with tin prevents the development of" exact="hypertension" post="in spontaneously hypertensive ratsScience198924338839010.1126/science.24921162492116 156.PuriN.ArefievY.ChaoR.SacerdotiD.ChaudryH.NicholsA.SrikanthanK.NawabA.SharmaD.LakhaniV.H.et al.Heme Oxygenase Induction Suppresses"/>
  <result pre="hypertension in spontaneously hypertensive ratsScience198924338839010.1126/science.24921162492116 156.PuriN.ArefievY.ChaoR.SacerdotiD.ChaudryH.NicholsA.SrikanthanK.NawabA.SharmaD.LakhaniV.H.et al.Heme Oxygenase Induction Suppresses" exact="Hepatic" post="Hepcidin and Rescues Ferroportin and Ferritin Expression in Obese"/>
  <result pre="Protection against Obesity-Induced Oxidative Stress, Inflammation, and Markers of Insulin" exact="Resistance" post="Accompanied with Conversion of White to Beige Fat in"/>
  <result pre="MiceAntioxidants2020948910.3390/antiox9060489 158.RaffaelleM.L.AminS.AlexR.ShenH.H.SinghS.VanellaL.RezzaniR.BonominiF.PetersonS.J.AbrahamN.G.Dietary Supplementation of Cold Press Pomegranate Seed Oil Attenuates" exact="Hepatic" post="Steatosis Fibrosis through Antioxidant and Mitochondrial Pathways in Obese"/>
  <result pre="158.RaffaelleM.L.AminS.AlexR.ShenH.H.SinghS.VanellaL.RezzaniR.BonominiF.PetersonS.J.AbrahamN.G.Dietary Supplementation of Cold Press Pomegranate Seed Oil Attenuates Hepatic" exact="Steatosis" post="Fibrosis through Antioxidant and Mitochondrial Pathways in Obese MiceInt."/>
  <result pre="Pomegranate Seed Oil Attenuates Hepatic Steatosis Fibrosis through Antioxidant and" exact="Mitochondrial" post="Pathways in Obese MiceInt. J. Mol. Sci.2020under review 159.Sayed-TabatabaeiF.A.OostraB.A.IsaacsA.van"/>
  <result pre="Angiotensinogen: A Mini ReviewN. Am. J. Med. Sci. (Boston)2011418319010.7156/v4i4p18322389749 162.YiannikourisF.GupteM.PutnamK.ThatcherS.CharnigoR.RateriD.L.DaughertyA.CassisL.A.Adipocyte" exact="deficiency" post="of angiotensinogen prevents obesity-induced hypertension in male miceHypertension2012601524153010.1161/HYPERTENSIONAHA.112.19269023108647 163.SlamkovaM.ZoradS.KrskovaK.Alternative"/>
  <result pre="J. Med. Sci. (Boston)2011418319010.7156/v4i4p18322389749 162.YiannikourisF.GupteM.PutnamK.ThatcherS.CharnigoR.RateriD.L.DaughertyA.CassisL.A.Adipocyte deficiency of angiotensinogen prevents obesity-induced" exact="hypertension" post="in male miceHypertension2012601524153010.1161/HYPERTENSIONAHA.112.19269023108647 163.SlamkovaM.ZoradS.KrskovaK.Alternative renin-angiotensin system pathways in adipose"/>
  <result pre="the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and" exact="colorectal cancer" post="riskJAMA20083001523153110.1001/jama.300.13.152318827209 Figure 1 This represents the spike protein of"/>
  <result pre="adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal" exact="cancer" post="riskJAMA20083001523153110.1001/jama.300.13.152318827209 Figure 1 This represents the spike protein of"/>
  <result pre="HO-1 gene expression. (Right) Unbound COVID-19 binds ACE-2 receptor with" exact="lower" post="affinity than porphyrin, and upon internalization into the cell,"/>
  <result pre="with the longer GT repeat allele HO-1 genetic polymorphism has" exact="lower" post="HO-1 expression and decreased endothelial hemostasis. Rapid CYP2D6 metabolizers"/>
  <result pre="endothelium in the lungs, kidney, and the rest of the" exact="cardiovascular" post="system. Figure 6 As ATPase activity increases, more electrons"/>
  <result pre="[85,86,87] and bilirubin blocks ROS action and increases resistance to" exact="hepatic steatosis." post="[88,89]. Figure 7 ACE-2 is overexpressed in adipose tissue"/>
  <result pre="[88,89]. Figure 7 ACE-2 is overexpressed in adipose tissue in" exact="obesity" post="and diabetes allowing COVID-19 to infect the cell. Lean"/>
  <result pre="7 ACE-2 is overexpressed in adipose tissue in obesity and" exact="diabetes" post="allowing COVID-19 to infect the cell. Lean (brown adipocyte)"/>
  <result pre="levels of ROS and upregulation of ACE-2 receptors, especially in" exact="morbid obesity" post="and diabetes. COVID-19 patients with high amounts of white"/>
  <result pre="of ROS and upregulation of ACE-2 receptors, especially in morbid" exact="obesity" post="and diabetes. COVID-19 patients with high amounts of white"/>
  <result pre="ACE polymorphism have the lowest ACE activity, which leads to" exact="lower" post="levels of ANG-II and less inflammation. antioxidants-09-00636-t001_Table 1Table 1"/>
  <result pre="scenarios caused by dysfunction of these hemoproteins. Key: AKI =" exact="acute" post="kidney injury, ARF = acute renal failure, CHF ="/>
  <result pre="caused by dysfunction of these hemoproteins. Key: AKI = acute" exact="kidney injury," post="ARF = acute renal failure, CHF = congestive heart"/>
  <result pre="these hemoproteins. Key: AKI = acute kidney injury, ARF =" exact="acute" post="renal failure, CHF = congestive heart failure, AOCI ="/>
  <result pre="hemoproteins. Key: AKI = acute kidney injury, ARF = acute" exact="renal failure," post="CHF = congestive heart failure, AOCI = anemia of"/>
  <result pre="acute kidney injury, ARF = acute renal failure, CHF =" exact="congestive heart failure," post="AOCI = anemia of chronic inflammation. Consequences of Hemoprotein"/>
  <result pre="kidney injury, ARF = acute renal failure, CHF = congestive" exact="heart" post="failure, AOCI = anemia of chronic inflammation. Consequences of"/>
  <result pre="acute renal failure, CHF = congestive heart failure, AOCI =" exact="anemia" post="of chronic inflammation. Consequences of Hemoprotein Malfunction/Deficiency Hemoprotein Deficiency"/>
  <result pre="failure, CHF = congestive heart failure, AOCI = anemia of" exact="chronic" post="inflammation. Consequences of Hemoprotein Malfunction/Deficiency Hemoprotein Deficiency Consequence Clinical"/>
  <result pre="= anemia of chronic inflammation. Consequences of Hemoprotein Malfunction/Deficiency Hemoprotein" exact="Deficiency" post="Consequence Clinical Manifestation Main Organs Affected Catalase â†‘ ROS"/>
  <result pre="[ACE-2R] organs Myoglobin â†‘ Rhabdomyolysis RhabdomyolysisAcute kidney injuryElectrolyte derangement Skeletal" exact="muscle" post="Hemoglobin â†&quot; O2 and CO2 affinityâ†&quot; Production Prolonged and"/>
  <result pre="deficiency. Allows COVID-19 to bind with high affinity leading to" exact="infection" post="Progressive tissue damage, especially as virus continues to replicate"/>
  <result pre="Allows COVID-19 to bind with high affinity leading to infection" exact="Progressive" post="tissue damage, especially as virus continues to replicate within"/>
 </snippets>
</snippetsTree>
